Literature DB >> 18752467

MAPK signalling in cardiovascular health and disease: molecular mechanisms and therapeutic targets.

Anthony J Muslin1.   

Abstract

Intracellular MAPK (mitogen-activated protein kinase) signalling cascades probably play an important role in the pathogenesis of cardiac and vascular disease. A substantial amount of basic science research has defined many of the details of MAPK pathway organization and activation, but the role of individual signalling proteins in the pathogenesis of various cardiovascular diseases is still being elucidated. In the present review, the role of the MAPKs ERK (extracellular signal-regulated kinase), JNK (c-Jun N-terminal kinase) and p38 MAPK in cardiac hypertrophy, cardiac remodelling after myocardial infarction, atherosclerosis and vascular restenosis will be examined, with attention paid to genetically modified murine model systems and to the use of pharmacological inhibitors of protein kinases. Despite the complexities of this field of research, attractive targets for pharmacological therapy are emerging.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18752467      PMCID: PMC2707780          DOI: 10.1042/CS20070430

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  103 in total

1.  Coupling of stress in the ER to activation of JNK protein kinases by transmembrane protein kinase IRE1.

Authors:  F Urano; X Wang; A Bertolotti; Y Zhang; P Chung; H P Harding; D Ron
Journal:  Science       Date:  2000-01-28       Impact factor: 47.728

2.  14-3-3 proteins block apoptosis and differentially regulate MAPK cascades.

Authors:  H Xing; S Zhang; C Weinheimer; A Kovacs; A J Muslin
Journal:  EMBO J       Date:  2000-02-01       Impact factor: 11.598

Review 3.  Mitogen-activated protein kinases in heart development and diseases.

Authors:  Yibin Wang
Journal:  Circulation       Date:  2007-09-18       Impact factor: 29.690

Review 4.  GPCR-jacking: from a new route in RTK signalling to a new concept in GPCR activation.

Authors:  Nicolas Delcourt; Joël Bockaert; Philippe Marin
Journal:  Trends Pharmacol Sci       Date:  2007-11-14       Impact factor: 14.819

Review 5.  Macrophages: an elusive yet emerging therapeutic target of atherosclerosis.

Authors:  R L Tiwari; V Singh; M K Barthwal
Journal:  Med Res Rev       Date:  2008-07       Impact factor: 12.944

Review 6.  Methods for studying signal-dependent regulation of translation factor activity.

Authors:  Xuemin Wang; Christopher G Proud
Journal:  Methods Enzymol       Date:  2007       Impact factor: 1.600

7.  NF1 regulates a Ras-dependent vascular smooth muscle proliferative injury response.

Authors:  Junwang Xu; Fraz A Ismat; Tao Wang; Jifu Yang; Jonathan A Epstein
Journal:  Circulation       Date:  2007-10-22       Impact factor: 29.690

8.  p38 mitogen-activated protein kinase inhibition decreases TNFalpha secretion and protects against left ventricular remodeling in rats with myocardial ischemia.

Authors:  Huiqiu Yin; Jidong Zhang; Haiqing Lin; Rong Wang; Yun Qiao; Bo Wang; Fenye Liu
Journal:  Inflammation       Date:  2007-10-18       Impact factor: 4.092

9.  Genetic inhibition of cardiac ERK1/2 promotes stress-induced apoptosis and heart failure but has no effect on hypertrophy in vivo.

Authors:  Nicole H Purcell; Benjamin J Wilkins; Allen York; Marc K Saba-El-Leil; Sylvain Meloche; Jeffrey Robbins; Jeffery D Molkentin
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-20       Impact factor: 11.205

Review 10.  Vascular injury and modulation of MAPKs: a targeted approach to therapy of restenosis.

Authors:  Pey-Jen Yu; Giovanni Ferrari; Luigi Pirelli; Iosif Gulkarov; Aubrey C Galloway; Paolo Mignatti; Giuseppe Pintucci
Journal:  Cell Signal       Date:  2007-03-15       Impact factor: 4.315

View more
  156 in total

1.  Thyroid hormone inhibits ERK phosphorylation in pressure overload-induced hypertrophied mouse hearts through a receptor-mediated mechanism.

Authors:  Jorge Suarez; Brian T Scott; Jorge A Suarez-Ramirez; Citlalic V Chavira; Wolfgang H Dillmann
Journal:  Am J Physiol Cell Physiol       Date:  2010-10-06       Impact factor: 4.249

2.  FGF23 induces left ventricular hypertrophy.

Authors:  Christian Faul; Ansel P Amaral; Behzad Oskouei; Ming-Chang Hu; Alexis Sloan; Tamara Isakova; Orlando M Gutiérrez; Robier Aguillon-Prada; Joy Lincoln; Joshua M Hare; Peter Mundel; Azorides Morales; Julia Scialla; Michael Fischer; Elsayed Z Soliman; Jing Chen; Alan S Go; Sylvia E Rosas; Lisa Nessel; Raymond R Townsend; Harold I Feldman; Martin St John Sutton; Akinlolu Ojo; Crystal Gadegbeku; Giovana Seno Di Marco; Stefan Reuter; Dominik Kentrup; Klaus Tiemann; Marcus Brand; Joseph A Hill; Orson W Moe; Makoto Kuro-O; John W Kusek; Martin G Keane; Myles Wolf
Journal:  J Clin Invest       Date:  2011-10-10       Impact factor: 14.808

Review 3.  Smad linker region phosphorylation in the regulation of extracellular matrix synthesis.

Authors:  Micah L Burch; Wenhua Zheng; Peter J Little
Journal:  Cell Mol Life Sci       Date:  2010-09-04       Impact factor: 9.261

4.  Tumor suppressor A20 protects against cardiac hypertrophy and fibrosis by blocking transforming growth factor-beta-activated kinase 1-dependent signaling.

Authors:  He Huang; Qi-Zhu Tang; Ai-Bing Wang; Manyin Chen; Ling Yan; Chen Liu; Hong Jiang; Qinglin Yang; Zhou-Yan Bian; Xue Bai; Li-Hua Zhu; Lang Wang; Hongliang Li
Journal:  Hypertension       Date:  2010-06-28       Impact factor: 10.190

Review 5.  Proteinaceous cysteine protease inhibitors.

Authors:  G Dubin
Journal:  Cell Mol Life Sci       Date:  2005-03       Impact factor: 9.261

6.  The protective role of 5-hydroxymethyl-2-furfural (5-HMF) against acute hypobaric hypoxia.

Authors:  Ming-Ming Li; Li-Ying Wu; Tong Zhao; Kui-Wu Wu; Lei Xiong; Ling-Ling Zhu; Ming Fan
Journal:  Cell Stress Chaperones       Date:  2011-04-15       Impact factor: 3.667

7.  A Novel Class of Common Docking Domain Inhibitors That Prevent ERK2 Activation and Substrate Phosphorylation.

Authors:  Rachel M Sammons; Nicole A Perry; Yangmei Li; Eun Jeong Cho; Andrea Piserchio; Diana P Zamora-Olivares; Ranajeet Ghose; Tamer S Kaoud; Ginamarie Debevec; Chandra Bartholomeusz; Vsevolod V Gurevich; Tina M Iverson; Marc Giulianotti; Richard A Houghten; Kevin N Dalby
Journal:  ACS Chem Biol       Date:  2019-05-13       Impact factor: 5.100

8.  Growth differentiation factor (GDF)-15 blocks norepinephrine-induced myocardial hypertrophy via a novel pathway involving inhibition of epidermal growth factor receptor transactivation.

Authors:  Xin-ye Xu; Ying Nie; Fang-fang Wang; Yan Bai; Zhi-zhen Lv; You-yi Zhang; Zi-jian Li; Wei Gao
Journal:  J Biol Chem       Date:  2014-02-19       Impact factor: 5.157

9.  Modulation of apoptosis by sulforaphane is associated with PGC-1α stimulation and decreased oxidative stress in cardiac myoblasts.

Authors:  Rafael O Fernandes; Jéssica H P Bonetto; Boran Baregzay; Alexandre L de Castro; Stephanie Puukila; Heidi Forsyth; Paulo C Schenkel; Susana F Llesuy; Ilma Simoni Brum; Alex Sander R Araujo; Neelam Khaper; Adriane Belló-Klein
Journal:  Mol Cell Biochem       Date:  2014-12-07       Impact factor: 3.396

10.  Interference with ERK(Thr188) phosphorylation impairs pathological but not physiological cardiac hypertrophy.

Authors:  Catharina Ruppert; Katharina Deiss; Sebastian Herrmann; Marie Vidal; Mehmet Oezkur; Armin Gorski; Frank Weidemann; Martin J Lohse; Kristina Lorenz
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-15       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.